Credit: Getty Images. Pombiliti must be administered in combination with Opfolda. The Food and Drug Administration (FDA) has approved Pombiliti ™ (cipaglucosidase alfa-atga) in combination with ...
Pompe disease is a rare genetic disorder that impacts both children and adults. It’s important to understand the next steps following a Pompe disease diagnosis to help prepare you and your loved ones ...
TOKYO, Jan. 20, 2023 /PRNewswire/ -- Astellas Pharma Inc. (ALPMF) (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") today announced that the U.S. Food and Drug Administration (FDA) has ...
(RTTNews) - Astellas Pharma Inc. (ALPMY, ALPMY) announced positive interim safety data from FORTIS Study. The Phase I/II clinical trial evaluated AT845, an investigational adeno-associated virus (AAV) ...
An Amicus Therapeutics combination treatment for the rare enzyme deficiency Pompe disease now has FDA approval, giving the drugmaker the opportunity to help patients who don’t respond to Sanofi ...
Credit: Getty Images. AT-GAA consists of cipaglucosidase alfa administered in conjunction with miglustat. The Food and Drug Administration has accepted for review the Biologics License Application for ...
Opfolda (miglustat) is a medicine taken with another medicine for certain people with late-onset Pompe disease. Pompe disease is a rare genetic disorder that is caused by an abnormal gene for a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback